Encellin, a San Francisco, CA-based personalized regenerative medicine biotech company developing novel cell-based approaches to deliver sustained therapies with a single implant, raised $5.9M in seed financing.
The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.
The company intends to use the funds to advance development of its technology platform and programs in hypoglycemia and hypocalcemia, to build out the laboratory, expand the team and into areas with readily available renewable cell sources and engineered cells, to encapsulate any cellular cargo in products from its proprietary platform.
Led by Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin is developing regenerative materials using cell transplant therapy. The company has developed cell transplant therapy for treating missing, damaged, or diseased cells and treatment of chronic diseases beginning with hypoglycemia and hypocalcemia. Its soft cell encapsulation device (CED) functions like a pouch to hold cells and help these cells survive in the body. Encellin’s CED allows enclosed cells to function like smart molecular factories, releasing therapeutics when needed.
FinSMEs
09/08/2021